The latest financial statement is for the quarter ending 2025-09-27.
| Cash Flow | 2025-09-27 | 2025-06-28 |
|---|---|---|
| Net income (loss) | 4,006 | 5,950 |
| Depreciation and amortization | 11,403 | 23,914 |
| Provision (benefit) for credit losses | 101 | 843 |
| Equity-based compensation | 3,176 | 6,057 |
| Change in fair value of contingent consideration | 0 | 0 |
| Impairment of assets | 0 | 0 |
| Loss on extinguishment | -326 | - |
| (gain) loss on disposals | 1 | -82 |
| Deferred income taxes | 135 | 87 |
| Unrealized gain on foreign currency fluctuations | -32 | 365 |
| Other, net | 243 | 763 |
| Accounts receivable | -1,824 | 4,625 |
| Inventories | -291 | 4,690 |
| Accounts payable and accrued expenses | 7,311 | -22,681 |
| Other current and noncurrent assets and liabilities | -1,251 | -1,272 |
| Net cash from operating activities | 30,098 | 6,607 |
| Settlement from the sale of a business | 0 | 686 |
| Purchase of property and equipment | 473 | 1,509 |
| Investments and acquisition of distribution rights | 0 | 0 |
| Net cash from investing activities | -473 | -2,195 |
| Proceeds from issuance of class a common stock | 96 | 1,467 |
| Tax withholdings on equity-based compensation | 9 | - |
| Payment of contingent consideration | 0 | 19,771 |
| Borrowing on revolver | 30,000 | 15,000 |
| Payment on revolver | 10,000 | 10,000 |
| Proceeds from the issuance of long-term debt, net of discount | 31,907 | - |
| Payments on the extinguishment of long-term debt | 65,765 | - |
| Debt refinancing costs | 697 | 0 |
| Scheduled payments on long-term debt | 5,302 | 0 |
| Other, net | -207 | -412 |
| Net cash from financing activities | -19,977 | -13,716 |
| Effect of exchange rate changes on cash | -394 | 632 |
| Net change in cash and cash equivalents | 9,254 | -8,672 |
| Cash and cash equivalents at beginning of period | 41,582 | - |
| Cash and cash equivalents at end of period | 42,164 | - |
Bioventus Inc. (BVS)
Bioventus Inc. (BVS)